Fundamentalsinfo compiles publicly available fundamental information on Indian listed companies to help you do your own analysis.

All Reports

Vinati Organics Limited

NSE: VINATIORGAMid CapSpecialty Chemicals

Current Price

1,330.35

As of 20 May 2026

Market Cap

₹14.40K Cr

As of 20 May 2026

specialty chemicals niche leader, global #1 in ATBS + IBB

Report updated: 2026-05-19

fundamentalsinfo.comLive

Vinati Organics Limited

NSE: VINATIORGA· Specialty Chemicals· Mid Cap

Specialty chemicals niche leader — global #1 in ATBS (~65% share) and IBB. Phase-2 ATBS expansion (50 to 60 KTPA) commissioning Apr-26; Veeral Organics subsidiary still scaling with the new MEHQ-Guaiacol process being re-engineered. FY26 closed flat at Revenue Rs.2,227 Cr (consolidated), PAT Rs.444 Cr (+9.5% YoY); PAT margin moved from 18.0% (FY25) to 19.9% (FY26) on lower raw-material prices. Promoter (Saraf family) holds 74.28% — only ~12% free float. CARE AA+/A1+ Stable, third year at AA+. Zero long-term debt. CMP Rs.1,329 / mkt cap Rs.13,868 Cr.

Rs.1,329

Share price (19 May 2026)

Rs.13,868 Cr

Market cap

Rs.2,227 Cr

FY26 revenue (flat YoY)

Rs.444 Cr

FY26 PAT (+9.5% YoY)

31.2 / 26-28%

P/E (TTM) / EBITDA margin band

74.28%

Promoter holding (8 holders)

Stock Funda Summary

  • Vinati Organics Limited (NSE: VINATIORGA / BSE: 524200) is a specialty chemicals company led by Vinati Saraf Mutreja (MD & CEO, daughter of founder Vinod Saraf).
  • Two global #1 positions: ATBS (~65% global market share — oilfield EOR + water treatment + acrylic fibre) and IBB (ibuprofen feedstock).
  • FY26 consolidated: Rev Rs.2,227 Cr (flat YoY), PAT Rs.444 Cr (+9.5%).
  • Single integrated plant at Lote (Maharashtra), 58% renewable power.
  • ATBS Phase 1 (40→50 KTPA) commissioned Aug-2025
  • Phase 2 (→60 KTPA) commissioning Apr-2026 with order book oversold.
  • Antioxidants turnaround real — 25% util (Q3FY24) → 60% (Q2FY26), profitability achieved.
  • Veeral Organics wholly-owned subsidiary carrying Rs.500 Cr capex envelope — MEHQ+Guaiacol being re-engineered, Anisole+4-MAP+PTAP+TAA commercial revenues from Oct-2026 onwards.
  • CARE AA+/A1+ Stable held 3 years (upgraded from AA in Oct-2023 on FY23 30% revenue growth + VAPL merger).
  • CFO succession Nov-2025: N.K.
  • Goyal retired (superannuation), Gulshan Kumar Sakhuja in (ex-HEG CFO, 11-month internal grooming from Dec-2024).
  • Promoter holding 74.28% (8 holders) — extremely thin public float.

Educational content only. Not SEBI-registered investment advice. This is public source-based data. Do your own analysis.